Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Mallinckrodt
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,410,524

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,410,524 protect, and when does it expire?

Patent 6,410,524 protects INSPRA and is included in one NDA.

Protection for INSPRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in twenty-seven countries.

Summary for Patent: 6,410,524
Title: Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
Abstract:Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.
Inventor(s): Perez; Alfonzo T. (Lake Forest, IL), Asner; Debra J. (Morton Grove, IL), LaChapelle; Richard J. (Wilmette, IL), Alexander; John C. (Princeton, NJ), Roniker; Barbara (Chicago, IL)
Assignee: G. D. Searle & Co. (Chicago, IL)
Application Number:09/434,685
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,410,524

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Baxter
Mallinckrodt
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.